Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

67.8K
Overview
67.8K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

688
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
688

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

Molecular cancer therapeutics·2026
Same author

Rat somatic genome editing enables ER+ breast cancer modeling.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Chronotropic index mediates the relationship between lower-limb loss level and 6-minute walk test performance.

Frontiers in sports and active living·2026
Same author

ICAM1high Neutrophils Sculpt Tumor Evolution and Metastasis through Symbiotic Adhesion and Reverse Migration.

Cancer research·2026
Same author

Performance Evaluation of a Novel Non-Invasive Monitoring Device for At-Home Neutropenia Detection in a Multicenter Cancer Cohort.

American journal of hematology·2026
Same author

Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025.

Cancer·2026

相关实验视频

Updated: Jun 13, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K

固体瘤诱导的系统性免疫抑制涉及二分化的骨髓状B细胞相互作用.

Xiaoxin Hao1,2,3,4, Yichao Shen1,2,4,5,6, Jun Liu1,2,5

  • 1Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.

Nature cell biology
|September 12, 2024
PubMed
概括

固体瘤会导致免疫抑制,影响髓状细胞和T细胞. 这项研究确定了两种瘤诱导的B细胞异常 (TiBA) 模式,即TiBA-1和TiBA-2,与骨髓变化有关,并可能指导定制的癌症免疫疗法.

更多相关视频

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

相关实验视频

Last Updated: Jun 13, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

305

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 细胞生物学 细胞生物学

背景情况:

  • 固体瘤诱导全身免疫抑制,主要影响髓状细胞和T细胞.
  • B细胞参与瘤诱导的免疫抑制的理解较少.
  • 了解B细胞动态对于全面的癌症免疫学至关重要.

研究的目的:

  • 识别和描述瘤诱导的B细胞异常 (TiBA) 的不同模式.
  • 调查TiBA亚型与骨髓形成之间的关联.
  • 探索TiBA在三阴性乳腺癌 (TNBC) 患者的临床相关性.

主要方法:

  • 在瘤载体模型中分析B细胞群和骨髓形成.
  • 描述两个不同的TiBA模式 (TiBA-1和TiBA-2).
  • 在接受免疫治疗的TNBC患者中,TiBA概况与临床结果的相关性.

主要成果:

  • 发现了两种新的TiBA模式,TiBA-1和TiBA-2,两者都与异常的骨髓骨髓形成有关.
  • TiBA-1涉及影响B细胞发育的利基竞争,而TiBA-2则由中性粒细胞驱动的早期B细胞积累.
  • 与TiBA-2相关的B细胞促进T细胞耗尽,TNBC患者的TiBA概况与免疫治疗反应相关.

结论:

  • 瘤诱导的系统性变化表现出显著的患者间多样性,涉及明显的B细胞和髓状细胞异常.
  • TiBA亚型代表了癌症免疫失调的关键指标.
  • 针对特定的B细胞和髓状细胞异常的个性化治疗策略是有效的癌症免疫治疗所必需的.